Company Performance - As of March 28, the stock price of Giant Star Medical Holdings (02393.HK) closed at HKD 0.108, up 8.0% with a trading volume of 2.0375 million shares and a turnover of HKD 21.22 million, showing a volatility of 8.0% [1] - Over the past month, Giant Star Medical Holdings has seen a cumulative increase of 42.86%, and a year-to-date increase of 61.29%, outperforming the Hang Seng Index by 17.54% [1] - For the fiscal year ending June 30, 2024, the company reported total revenue of CNY 1.274 billion, a year-on-year decrease of 13.51%, while net profit attributable to shareholders was CNY 1.089 billion, a significant increase of 30,014.43% [1] Industry Valuation - Currently, there are no institutional investment ratings for Giant Star Medical Holdings [2] - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -3.55 times, with a median of 4.98 times. Giant Star Medical Holdings has a P/E ratio of 0.2 times, ranking first in the industry [2] - Other companies in the industry include Jingjiu Kangliao (00648.HK) with a P/E ratio of 0.38 times, Global Medical (02666.HK) at 4.54 times, Yongsheng Medical (01612.HK) at 4.58 times, Ruici Medical (01526.HK) at 5.38 times, and New Century Medical (01518.HK) at 6.16 times [2] Company Overview - Giant Star Medical Holdings is recognized as one of China's leading high-margin medical consumables and equipment companies, focusing on high-margin medical consumables and equipment, specifically medical imaging products and in vitro diagnostic products [3] - The company has established a broad sales network in China and has gained the trust of international manufacturers such as Fujifilm, Roche Diagnostics, Becton Dickinson, and Thermo Fisher Scientific [3] - Giant Star Medical is the exclusive manufacturer of medical film for Fujifilm in China and one of the largest distributors of Roche's in vitro diagnostic products in the country [3] - The company aims to continue seeking potential acquisition opportunities and establish strategic partnerships with industry giants to strengthen its position in the medical industry [3]